Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery

NCT ID: NCT00942448

Last Updated: 2013-01-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

306 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is proposed to evaluate the efficacy and safety of single doses of Diclofenac HPBCD subcutaneous (s.c.) (25 mg/1 ml and 50 mg/1 ml) in the treatment of acute moderate-to-severe pain after dental impaction surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dental Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diclofenac HPBCD s.c. 25mg/ml

Group Type EXPERIMENTAL

Diclofenac HPBCD

Intervention Type DRUG

1 single injection at day of dental surgical extraction

Diclofenac HPBCD s.c. 50mg/ml

Group Type EXPERIMENTAL

Diclofenac HPBCD

Intervention Type DRUG

1 single injection at day of dental surgical extraction

Diclofenac HPBCD s.c. 75mg/ml

Group Type ACTIVE_COMPARATOR

Diclofenac HPBCD

Intervention Type DRUG

1 single injection at day of dental surgical extraction

Placebo s.c. (1ml)

Group Type PLACEBO_COMPARATOR

Placebo s.c.

Intervention Type OTHER

1 single injection at day of dental surgical extraction

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diclofenac HPBCD

1 single injection at day of dental surgical extraction

Intervention Type DRUG

Diclofenac HPBCD

1 single injection at day of dental surgical extraction

Intervention Type DRUG

Diclofenac HPBCD

1 single injection at day of dental surgical extraction

Intervention Type DRUG

Placebo s.c.

1 single injection at day of dental surgical extraction

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
* Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.
* Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.

Exclusion Criteria

* Surgery performed under general anaesthesia, or sedation.
* Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
* Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
* Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
* Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
* Hepatic or renal impairment.
* Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.
* Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
* Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
* Patients under treatment with any medication that may affect the treatment efficacy evaluation.
* Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IBSA Institut Biochimique SA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Dietrich, Prof

Role: PRINCIPAL_INVESTIGATOR

The school of dentistry, University of Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gabinet Stomatologiczny Bartek

Kobyłka, , Poland

Site Status

Centrum Leczenia Chorób Cywilizacyjnych

Warsaw, , Poland

Site Status

Niepubliczny Zakład Opieki Zdrowotnej

Warsaw, , Poland

Site Status

NZOZ Polimedica

Zgierz, , Poland

Site Status

The School of Dentistry; University of Birmingham

Birmingham, , United Kingdom

Site Status

Eastman Dental Institute, University College London

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09PUK-DCsc04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.